MedPath

HiDO Technologies Secures NIA Grant to Advance AI Dementia Care

• HiDO Technologies has been awarded a Phase II SBIR grant from the National Institute on Aging (NIA) to further develop its AI-driven dementia care technology. • The technology leverages facial recognition and video observation to enhance safety, improve health outcomes, and alleviate caregiver stress for dementia patients. • The grant will enable HiDO Technologies to accelerate the development and deployment of its innovative solutions for individuals living with dementia. • HiDO Technologies focuses on creating AI-driven solutions to improve care for people with chronic health conditions, including dementia.

HiDO Technologies has received a Phase II Small Business Innovation Research (SBIR) grant from the National Institute on Aging (NIA), a division of the National Institutes of Health (NIH), to advance its innovative dementia care technology. The grant, awarded under Award Number R44AG077737, will support the continued development of AI-driven solutions designed to improve the lives of individuals living with dementia and reduce the burden on their caregivers.
Charles Gellman, CEO of HiDO Technologies, stated, "Our team is thrilled to receive this Phase II grant from the NIA to continue this critical research that we believe will transform the lives for people living with dementia." The company's technology utilizes facial recognition and video observation to address critical needs in dementia care, focusing on ensuring safety, improving health outcomes, and reducing caregiver stress.

AI-Powered Dementia Care

HiDO Technologies' approach involves leveraging artificial intelligence to monitor and support individuals with dementia. By using facial recognition, the system can identify the patient and track their activities. Video observation provides insights into their behavior and environment, allowing for timely intervention if needed. This technology aims to provide a safety net for patients while also offering caregivers peace of mind.

Impact on Patients and Caregivers

The technology developed by HiDO Technologies has the potential to significantly improve the quality of life for both patients and caregivers. For patients, it offers enhanced safety and monitoring, which can help prevent accidents and ensure timely assistance. For caregivers, it reduces stress and provides valuable support, allowing them to better manage the demands of caring for a loved one with dementia.

About HiDO Technologies

HiDO Technologies is a medtech company specializing in developing AI-driven solutions to improve care for people with chronic health conditions, including dementia. The company's mission is to create technologies that enhance patient safety, support caregivers, and optimize healthcare delivery.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Fast-Tracks NeuroVive's Traumatic Brain Injury Drug

The FDA has granted Fast Track designation to NeuroVive's drug, NeuroSTAT, aimed at treating moderate to severe traumatic brain injury (TBI). This status accelerates the drug's development and review process, offering more frequent FDA interactions and feedback. NeuroSTAT works by protecting mitochondria, aiming to prevent secondary brain damage post-TBI, with hopes of improving survival, quality of life, and neurological function. Early trials have shown promising results, including a 35% decrease in brain injury volume in experimental models.

Kinoxis Therapeutics Receives $2.5M Grant to Advance KNX100 for Dementia Agitation

Kinoxis Therapeutics secured a $2.5 million grant to support its Phase 2a CARES-X clinical trial of KNX100 for dementia-related agitation.
The CARES-X trial, involving eight Australian sites, will assess KNX100's safety, tolerability, and efficacy over a four-week period.

FDA Approves AI Tool for ARIA Detection, Expands Nerivio Indication, and Grants Accelerated Approval to Gene Therapy for AADC Deficiency

The FDA cleared icobrain aria, the first AI software to detect and grade amyloid-related imaging abnormalities (ARIA) in Alzheimer's disease, enhancing patient safety during anti-amyloid treatments.
Theranica's Nerivio receives expanded FDA approval for acute migraine treatment in patients aged 8 and older, offering a needle-free, non-drug alternative for pediatric migraine.

FDA Clears Icobrain Aria: AI Tool for Enhanced ARIA Detection in Alzheimer's Treatments

The FDA has cleared Icobrain Aria, the first AI software for detecting and grading amyloid-related imaging abnormalities (ARIA) associated with Alzheimer's treatments.
Icobrain Aria uses brain MRI scans to generate a quantitative report, including severity scores for ARIA-edema and ARIA-hemorrhages, integrated into hospital workflows.

INmune Bio Completes Enrollment in Phase 2 Alzheimer's Trial Targeting Neuroinflammation

INmune Bio has finalized patient randomization for its Phase 2 trial (AD02) in early Alzheimer's disease, enrolling a total of 208 patients.
The trial focuses on individuals with elevated neuroinflammation biomarkers, with 56% having mild Alzheimer's and 44% with mild cognitive impairment.

FDA Clears HuidaGene's CRISPR/Cas13 RNA-Editing Therapy HG202 for nAMD

The FDA has cleared HuidaGene Therapeutics' IND application for HG202, a CRISPR/Cas13 RNA-editing therapy, for neovascular age-related macular degeneration (nAMD).
HG202 targets VEGF-A mRNA using a non-receptor binding pathway, potentially addressing resistance to current anti-VEGF therapies.

FDA Clears HuidaGene's IND for CRISPR/Cas13 RNA-Editing Therapy HG202 to Treat nAMD

HuidaGene Therapeutics received FDA clearance for its Investigational New Drug (IND) application for HG202, a CRISPR/Cas13 RNA-editing therapy targeting neovascular age-related macular degeneration (nAMD).
HG202 is the first CRISPR/Cas13 RNA-editing therapy to enter clinical trials globally, offering a novel approach by targeting VEGF-A mRNA without receptor binding.

Cenna Biosciences Awarded NIH Grant for Alzheimer's Disease Drug Development

Cenna Biosciences receives a $2.7M Phase II SBIR grant from the NIH's National Institute on Aging to advance Nubytide™ for Alzheimer's disease.
Nubytide™, a novel peptide drug, targets the production of toxic Aβ species, offering a potentially safer alternative to monoclonal antibody therapies.

Spark Biomedical Receives NIDA Funding to Develop AI for Opioid Withdrawal Detection

Spark Biomedical has been awarded a $318,875 SBIR grant from the National Institute on Drug Abuse (NIDA) to develop an AI algorithm for detecting opioid withdrawal symptoms and cravings.
The AI algorithm will analyze data from wearable devices that measure digital and physical biomarkers, along with clinical assessments, to proactively identify withdrawal symptoms.

Sinopia Biosciences Awarded $2.2M SBIR Grant to Advance Oral Mucositis Program

Sinopia Biosciences received a $2.2M Phase II SBIR grant from the NIDCR to advance its oral mucositis program, focusing on lead discovery and optimization.
The grant will support the use of Sinopia's LEADS® platform, which leverages AI/ML to identify therapeutic targets and candidates for oral mucositis.

Reference News

[1]
HiDO Technologies Awarded Phase II SBIR Grant by National Institute on Aging (NIA) for ... - PRWeb
prweb.com · Oct 2, 2024

HiDO Technologies received a Phase II grant from the NIA to continue dementia research using facial recognition and vide...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy